Eledon's 24-Month BESTOW Data and Fast Track Highlight Efficacy, But Financing Risk Persists

What happened

Eledon Pharmaceuticals presented updated 24-month data from the Phase 2 BESTOW extension showing tegoprubart maintained a 13 mL/min/1.73m² eGFR advantage over tacrolimus (71 vs 58) with no rejections beyond six months compared to seven in the tacrolimus arm. The company also announced FDA Fast Track designation for tegoprubart in prevention of kidney transplant rejection and reiterated plans to initiate the Phase 3 LEGACY study in Q4 2026. These results extend the renal function and tolerability differentiation seen at earlier timepoints but do not change the fact that the planned Phase 3 trial is a non-inferiority composite endpoint, not a superiority on kidney function. The core financing risk remains: as of June 30, 2026, Eledon had $88.8M in cash, used $45.3M in H1 2026, and lacks sufficient funds for 12 months, with additional capital required to start Phase 3. Fast Track may ease regulatory interactions but does not address the dilutive overhang from 48.7M warrants or the need for a well-structured financing.

Implication

The 24-month data strengthens the case that tegoprubart offers clinically meaningful renal function and safety advantages, which could drive adoption if Phase 3 proves non-inferior on rejection. However, the lack of late rejections comes from a small Phase 2 extension and may not translate to a larger trial where the primary endpoint includes biopsy-proven acute rejection. Fast Track designation could speed regulatory review but does not solve the immediate capital need; the company must raise funds before initiating Phase 3, likely before year-end. Investors should closely monitor any financing announcement and its terms, as a dilutive raise could wipe out gains from the positive clinical data. Until financing and trial startup are secured, the stock remains a WAIT with attractive entry near $2.40 and trim above $4.20 if the overhang clears.

Thesis delta

The updated long-term data and Fast Track status modestly increase confidence in tegoprubart's clinical profile but do not alter the central thesis that financing and Phase 3 execution are the primary near-term value drivers. The WAIT rating is maintained; however, the probability of a successful Phase 3 may have increased if the renal function advantage translates into meaningful differentiation on the non-inferiority endpoint. The valuation scenarios remain unchanged until financing terms are known.